Overview: BSI-038 is an anti-CD40 humanized agonist monoclonal antibody with 7-fold higher binding affinity and 4-fold higher cellular bioactivity compared to selicrelumab. By binding to CD40 receptor, it triggers the cellular proliferation and activation of antigen-presenting cells. BSI-038 was created by Biosion under a collaboration with CTTQ in Jul 2019. CTTQ owns Greater China rights while Biosion retains rights to development and commercialization in the rest of the world.

Development status: CTTQ is conducting a Phase 1 clinical study of BSI-038 in advanced tumors in China.